News

An artist with epidermolysis bullosa (EB) is among the 10 creators selected as the winners of the 2026 RARE Artist program. The program is run by the Rare Foundation, an advocacy group that works to raise awareness and promote legislation to improve the lives of people with rare…

Recruitment is now underway in a new Phase 3 clinical trial testing SD-101, an experimental cream designed to promote wound healing in people with epidermolysis bullosa (EB). The Phase 3 SD-007 study (NCT07482787) is open to children, ages four weeks through 12 years, who have EB simplex,…

In the week leading up to Halloween, advocates around the world will wear their clothes inside out to raise awareness of epidermolysis bullosa (EB). EB Awareness Week runs this year from Sunday, Oct. 25, to Saturday, Oct. 31. The Inside Out campaign is being spearheaded by DEBRA International,…

Off-label treatment with apremilast, an oral medication approved for certain inflammatory conditions, helped prevent new inflammatory blisters in an older woman with epidermolysis bullosa acquisita (EBA), a rare autoimmune disease in which blisters form in layers of the skin in response to injury. The 69-year-old woman, who had…

An interview study found that epidermolysis bullosa (EB) can affect nearly every part of children’s daily lives. The children described constant pain and wound care, fear of new wounds, emotional strain, social isolation, and difficulty taking part in normal childhood activities. “Pediatric nurses should provide holistic and child-centered care…

Tiny packets of cellular cargo called extracellular vesicles (EVs) that are released from placental cells may help calm the chronic inflammation that drives scarring and tissue damage in people with recessive dystrophic epidermolysis bullosa (RDEB), a new study found. In laboratory experiments, these extracellular vesicles shifted inflammatory immune cells…

A cell-based study found that a group of experimental drugs designed to restore missing protein production in junctional epidermolysis bullosa (JEB) showed different responses to specific mutations in the COL17A1 gene, a finding researchers said could be used to work toward tailored treatment approaches. The researchers also identified a…

Zevaskyn (prademagene zamikeracel), a gene therapy approved in the U.S. last year to treat the fragile skin disease recessive dystrophic epidermolysis bullosa (RDEB), can now be administered at University of Florida Health, a university-affiliated clinic in Gainesville. That’s according to Abeona Therapeutics, the company that markets Zevaskyn, which…

Children with severe epidermolysis bullosa (EB) who take fiber or iron supplements are likely to take laxatives as well,  a retrospective study in the U.K. found. “Total fibre intake did not reduce the reliance on laxatives or improve stool consistency and frequency in children and adolescents with EB,” the…

Inmune Bio plans to submit regulatory applications in the U.K., U.S., and European Union seeking approval of Ebstrocel, its experimental stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company expects to file its application in the U.K. before the end of this year, followed by…

Caring for a child with epidermolysis bullosa (EB) is often logistically challenging, socially fraught, and emotionally exhausting, a new Spanish study underscores. Based on the findings, researchers are calling for more proactive support to be given to families affected by EB. “The findings highlight the need for a more…

Children with recessive dystrophic epidermolysis bullosa (RDEB) and their parents reported less pain and itch, better wound healing, and greater participation in daily activities after treatment with Inmune Bio’s Ebstrocel, an experimental stem cell therapy, during the MissionEB trial, according to a new analysis. The findings build on…